Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>Here are the key points:The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the coming quarters. Total earnings for the 62 S&P 500 companies that have ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Johnson & Johnson (JNJ) announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with treatment-resistant depression (TRD).Spravato is presently approved in combination with an oral antidepressant to treat adults with TRD and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.Following the latest nod, Spravato became the first and only monotherapy fo ...

Financial Data and Key Metrics - The company will review its business results for the fourth quarter and full year 2024, along with the financial outlook for 2025 [3] Business Line Data and Key Metrics - No specific data provided in the content regarding individual business line performance or key metrics Market Data and Key Metrics - No specific data provided in the content regarding market performance or key metrics Company Strategy and Industry Competition - The presentation contains forward-looking statements regarding the company's future operating and financial performance, market position, and business strategy [4] Management Commentary on Operating Environment and Future Outlook - No specific commentary provided in the content regarding the operating environment or future outlook Other Important Information - Additional materials, including the presentation and associated schedules, are available on the Investor Relations section of the Johnson & Johnson website [3] Q&A Session Summary - No Q&A session details provided in the content

Core Insights - Johnson & Johnson (J&J) reported fourth-quarter 2024 earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $2.00, but reflecting a 10.9% decline year over year [1] - Total sales for the quarter reached $22.52 billion, slightly surpassing the Zacks Consensus Estimate of $22.51 billion, with a year-over-year increase of 5.3% [2] Financial Performance - Adjusted earnings, excluding intangible amortization and special items, were reported at $1.41 per share, down 17.1% from the previous year [1] - Full-year 2024 sales increased by 4.3% to $88.82 billion, slightly missing the Zacks Consensus Estimate of $88.84 billion [16] Segment Performance - The Innovative Medicines segment saw sales rise 4.4% year over year to $14.33 billion, driven by key products like Darzalex and new drugs such as Carvykti and Tecvayli [5][6] - MedTech segment sales reached $8.19 billion, up 6.7% year over year, but missed the Zacks Consensus Estimate of $8.25 billion [14] Market Dynamics - Domestic sales increased by 10% to $13.2 billion, while international sales declined by 0.7% to $9.32 billion, impacted by currency fluctuations [3] - The Innovative Medicines unit outperformed expectations, while the MedTech unit faced challenges, particularly in the Asia Pacific region due to competitive pressures and government cost containment efforts in China [15][19] Future Outlook - For 2025, J&J expects sales in the range of $89.2 billion to $90.0 billion, which is below the Zacks Consensus Estimate of $91.2 billion, indicating a growth of 0.5%-1.5% [17] - Adjusted earnings per share for 2025 are projected to be between $10.50 and $10.70, suggesting a growth of 5.2% to 7.2% [18] Strategic Moves - J&J has been active in acquisitions, including the recent agreement to acquire Intra-Cellular Therapies for approximately $14.6 billion, which will enhance its neuroscience pipeline [23][22]

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Johnson & Johnson (JNJ) reported $22.52 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 5.3%. EPS of $2.04 for the same period compares to $2.29 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $22.51 billion, representing a surprise of +0.06%. The company delivered an EPS surprise of +2.00%, with the consensus EPS estimate being $2.00.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

4th Quarter 2024 Earnings Call January 22, 2025 Cautionary note on Forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying ...

Key TakeawaysJohnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for one-time costs like acquisitions, the drug and medical device maker's adjusted profits beat estimates.The company's projections for sales during the 2025 fiscal year also came in short of current analyst estimates. Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate. Although sales surged in the Innovative Medicine ...